dietmar_berger

Dr Dietmar Berger returns to big pharma

pharmafile | May 31, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Atara, R&D, Sanofi, oncology, pharma, research 

Industry veteran Dr Dietmar Berger has joined Sanofi as the company’s new Global Head of Development. Dr Berger joins the French firm after spending a year at US biotech Atara Biotherapeutics.

Having graduated from the University of Freiberg in 1988 Dr Berger spent the bulk of his career rising through the ranks of big pharma, taking on positions at Amgen, Bayer and Genentech.

However in May of last year, Dr Berger joined T-cell immunotherapy biotech Atara as their Global Head of R&D. Dr Berger said he chose to leave Atara in order to pursue other opportunities – analysts have suggested his move was a response to being overlooked as CEO.

Advertisement

With his new role at Sanofi, Dr Berger has returned to the world of big pharma in which he has forged his twenty year career.

Sanofi announced the appointment via twitter: “Dietmar Berger, MD, PhD, joins #Sanofi as Head of Development, overseeing our clinical portfolio across all therapeutic areas and helping us bring transformative new medicines to patients.”

Related Content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

The Gateway to Local Adoption Series

Latest content